Company: SHPH
Filing Date: 2025-03-19
Form Type: PRE 14A
Source: 0001493152-25-010886
Chunk: 17

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-19
Form: PRE 14A
Chunk 17
---
:----|:----------------|:--|:----|:------------------------------------------------|-------:|:----|:--------------------------------------------|-------:|
| Mira Jung1      |     |        | 5/1/23  |     |                                                              | - |     |                                                                | - |     |                    | - |     |                 | - |     |                                                 |  1,194 |     | $                                           |  1,026 |
| Timothy Lorber2 |     |        | 6/13/24 |     |                                                              | - |     |                                                                | - |     |                    | - |     |                 | - |     |                                                 | 28,455 |     | $                                           | 24,443 |

| (1) | These                                                                                   
 restricted stock units vest in two installments on the anniversary of the grant date.   |
| (2) | These                                                                                   
 restricted stock units vest in three installments on the anniversary of the grant date. |

Each of our executive officers has entered into an employment agreement with us. The employees each will receive compensation on an annual basis in cash, payable in monthly installments commencing at the completion of our IPO, as well as restricted stock units (“RSUs”) subject to achieving certain key performance indicators. Certain of our executive officers are entitled to various target bonuses, upon achievement of certain milestones. The terms of the employment agreements are as follows:

| 15 |

Employment Agreement with Anatoly Dritschilo, MD

On June 28, 2019, we entered into an employment agreement with our Co-Chief Executive Officer and Chairman of the board of directors, Anatoly Dritschilo, M.D. Under Dr. Dritschilo’s employment agreement, Dr. Dritschilo will receive base compensation of $274,000 per year. Dr. Dritschilo also received an initial RSU grant of 22,748 RSUs (2,844 on a post-reverse split basis) issuable under the Company’s 2018 Equity Incentive Plan (the “Plan”), which RSUs vested over three years in substantially equal one-third installments on each one year anniversary of the agreement. Under his employment agreement, if Dr. Dritschilo terminates his employment for “Good Reason,” as defined in the agreement, Dr. Dritschilo will be entitled to his then applicable base salary for period of 12 months, subject to his continued compliance with certain requirements of his employment agreement. Dr